Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A roadmap for the Human Developmental Cell Atlas

    Research output: Contribution to journalReviewResearchpeer-review

  2. Repositioning of the global epicentre of non-optimal cholesterol

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Germline Elongator mutations in Sonic Hedgehog medulloblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pan-cancer analysis of whole genomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown

    Research output: Contribution to journalLetterResearchpeer-review

  3. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Day-to-day measurement of physical activity and risk of atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  • MetaCardis Consortium
View graph of relations

Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.

Original languageEnglish
JournalNature
Volume581
Issue number7808
Pages (from-to)310-315
Number of pages6
ISSN0028-0836
DOIs
Publication statusPublished - 21 May 2020

ID: 59895538